

Resource Summary Report

Generated by [NIF](#) on Aug 5, 2026

HepG2-rNTCP-eGFP

RRID:CVCL_JY38

Type: Cell Line

Proper Citation

RRID:CVCL_JY38

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_JY38

Proper Citation: RRID:CVCL_JY38

Description: Cell line HepG2-rNTCP-eGFP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hepatoblastoma

Defining Citation: [PMID:20539008](#)

Comments: Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HepG2-rNTCP-eGFP

Synonyms: HepG2 FLAG-Ntcp-EGFP

Cross References: cancercellines:CVCL_JY38, Wikidata:Q54882856

ID: CVCL_JY38

Hierarchy: cvcl_0027

Record Creation Time: 20220427T220335+0000

Record Last Update: 20260802T001327+0000

Ratings and Alerts

No rating or validation information has been found for HepG2-rNTCP-eGFP.

No alerts have been found for HepG2-rNTCP-eGFP.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 151 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Song H, et al. (2023) TRIM25 inhibits HBV replication by promoting HBx degradation and the RIG-I-mediated pgRNA recognition. Chinese medical journal, 136(7), 799.

Zhou H, et al. (2023) Hepatitis B virus X protein induces ALDH2 ubiquitin-dependent degradation to enhance alcoholic steatohepatitis. Gastroenterology report, 11, goad006.

Zheng Y, et al. (2023) Hepatitis B virus hijacks TSG101 to facilitate egress via multiple vesicle bodies. PLoS pathogens, 19(5), e1011382.

Chen J, et al. (2023) A functional variant of CD40 modulates clearance of hepatitis B virus in hepatocytes via regulation of the ANXA2/CD40/BST2 axis. Human molecular genetics, 32(8), 1334.

Cai J, et al. (2023) Plerixafor and resatorvid inhibit hepatitis B virus in vitro by upregulating elongation factor Tu GTP-binding domain containing 2. Frontiers in cellular and infection microbiology, 13, 1118801.

Yuan S, et al. (2023) HBV X Protein Induces Degradation of UBXN7, a Novel Negative Regulator of NF- κ B Signaling, to Promote HBV Replication. Cellular and molecular gastroenterology and hepatology, 15(1), 179.

Nkongolo S, et al. (2023) Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8⁺ T cells. The Journal of clinical investigation, 133(1).

Liu Y, et al. (2023) Targeted viral adaptation generates a simian-tropic hepatitis B virus that infects marmoset cells. Nature communications, 14(1), 3582.

Yu Y, et al. (2023) An RNA-based system to study hepatitis B virus replication and evaluate antivirals. Science advances, 9(15), eadg6265.

Wu Q, et al. (2023) Presence of Intact Hepatitis B Virions in Exosomes. Cellular and molecular gastroenterology and hepatology, 15(1), 237.

Peng B, et al. (2023) Nonproductive Hepatitis B Virus Covalently Closed Circular DNA Generates HBx-Related Transcripts from the HBx/Enhancer I Region and Acquires

Reactivation by Superinfection in Single Cells. *Journal of virology*, 97(1), e0171722.

Radoshitzky SR, et al. (2023) Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. *Scientific reports*, 13(1), 3131.

Allweiss L, et al. (2023) Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure. *Gut*, 72(5), 972.

Xia Y, et al. (2023) Silencing of STE20-type kinase TAOK1 confers protection against hepatocellular lipotoxicity through metabolic rewiring. *Hepatology communications*, 7(4).

Burdette D, et al. (2023) Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection. *Antimicrobial agents and chemotherapy*, 67(1), e0134822.

Kim ES, et al. (2022) Hepatitis B virus X protein counteracts high mobility group box 1 protein-mediated epigenetic silencing of covalently closed circular DNA. *PLoS pathogens*, 18(6), e1010576.

Wu DQ, et al. (2022) SIRT2 Promotes HBV Transcription and Replication by Targeting Transcription Factor p53 to Increase the Activities of HBV Enhancers and Promoters. *Frontiers in microbiology*, 13, 836446.

Kim GW, et al. (2022) N6-methyladenosine modification of the 5' epsilon structure of the HBV pregenome RNA regulates its encapsidation by the viral core protein. *Proceedings of the National Academy of Sciences of the United States of America*, 119(7).

Fan SY, et al. (2022) Nicotinamide N-Methyltransferase inhibits HBV replication by suppressing NR5A1 expression invitro. *Biochemical and biophysical research communications*, 614, 70.

Liu L, et al. (2022) Hepatitis B virus promotes hepatocellular carcinoma development by activating GP73 to repress the innate immune response. *Infectious agents and cancer*, 17(1), 52.